The frequency of alterations in FCRL family genes exceeded 20% in melanoma, non-small cell lung cancer, breast cancer, lung cancer, hepatobiliary cancer, bladder cancer, endometrial cancer, colorectal cancer, and esophageal cancer, and the main types of alterations were mutations and amplifications (Figure 3A). This evidence concerns the gene FCRLA and urinary bladder cancer.